natgillin/translations-raw huggingface dataset:
a heavy chain comprising an HVR-H1 comprising the amino acid sequence of SEQ ID NO:41, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:65, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:89, and a light chain comprising an HVR-L1 comprising the amino acid sequence of SEQ ID NO:5, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:17, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:29; 
teški lanac koji obuhvaća HVR-H1 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 41, HVR-H2 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 65, i HVR-H3 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 89, te laki lanac koji obuhvaća HVR-L1 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 5, HVR-L2 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 17, i HVR-L3 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 29;
For example, as shown in FIG. 26, a compound of Formula 9 (which may be formed as described above with respect to FIG. 19) may be protected as a 7,9-acetal linked analog of Formula 21 (where R1═R2═Ph; P1=TBDMS; R7═CH3; R8═R9═H in generalized formula O of Scheme 6). 
Na primjer, kao što je prikazano na slici 26, spoj formule 9 (koji može biti izveden kao što je gore opisano u odnosu na sliku 19) može biti zaštićen kao 7,9-acetalno povezani analog formule 21 (gdje R=R>=Ph; P,=TBDMS; Rg=CH;i Rg=R.o=H u općoj formuli O iz sheme 6).
capable of improving one or more neurological functional measures more significantly than human fetal neuroprogenitor cells (hNPCs) in central nervous system injury or neurodegenerative models. 
sposobna za poboljšanje jedne ili više funkcionalnih mjera značajnije nego hNPCs u CNS ozlijedi ili neurodegnerativnim modelima.
Recombinant FSH according to any of paragraphs 16 to 19 which includes a2,6-sialylation in an amount which is from 15 to 35% of the total sialylation. Recombinant FSH according to any of paragraphs 16 to 20 which includes a sialic acid content [expressed in terms of a ratio of moles of sialic acid to moles of protein] of 6 mol/mol or greater. 
Farmaceutski pripravak koji sadrži rFSH uključujući 02,3-sialilaciju i 02,6-sialilaciju gdje 60% ili više od ukupne sialilacije je 02,3-sialilacija i od 5 do 40% od ukupne sialilacije je 02,6-sialilacija; te ima sadržaj sijalinske kiseline [izražen terminom omjera molova sijalinske kiseline prema molovima proteina] od 10 mol/mol do 16 mol/mol.
C1-3alkyl, optionally substituted with one to four groups selected from -F, -OH, and -SO2C1-3 alkyl; halogen; 
-3alkil, opcionalno supstituiran s jednom do četiri skupine odabrane od –F, –OH, i –SO2C1-3alkil; halogen; CN;
A driven gear 134 is coupled to the ball screw 48 for co-rotation of the driven gear and ball screw 48. 
Pogonjeni zupčanik je spojen na kuglasti vijak (48) kako bi se kuglasti vijak (48) i zupčanik zajedno okretali.
The aerosol generating means used in practicing the invention is physically separate from the fuel element. 
Sredstvo za generiranje aerosola je fizički odvojeno od gorivog elementa.
The method of item 72 or the compound, the polymorphic form, or the pharmaceutical composition for use according to item 72, or the use of item 72, wherein the lung disease is pulmonary inflammation, pulmonary fibrosis, COPD, asthma, cystic fibrosis, or idiopathic pulmonary fibrosis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je plućna bolest odabrana od upale pluća, plućne fibroze, KOPB, astme, cistične fibroze, te idiopatske plućne fibroze.
reacting the crystalline nilotinib L-tartrate with a base to obtain a nilotinib base; and reacting the nilotinib base with HCl. 
reakciju kristalnog nilotinib L-tartrata sa bazom da se dobije baza nilotiniba; te reakciju baze nilotiniba s HCl.
At its peak effect (10 min) dextromethorphan did not cause a significant effect (p=0.07; Mann-Whitney U test), while tolperisone (p=0.0059; Mann-Whitney U test) and its combination with dextromethorphan (p=0.00031; Mann-Whitney U test) did. 
Kod vršnog učinka (10 min) dekstrometorfan nije uzrokovao značajan učinak (p = 0,07; Mann-Whitney-ev U test), dok tolperison (p = 0,0059; Mann-Whitney-ev U test) i njegova kombinacija s dekstrometorfanom jesu (p = 0,00031; Mann-Whitney-ev U test).
A combination according to claim 9 characterised in that the polymorph provides an XRPD pattern comprising peaks substantially as set out in Table 4. 
Polimorf u skladu s patentnim zahtjevom 2, naznačen time što osigurava uzorak XRPD koji sadrži maksimume kao što su iznijeti u Tablici 4:
A multi-stage, oral-fluid collection and testing device for collecting and testing an oral-fluid for substances, the testing device comprising: 
Višestupanjska naprava, (100) za prikupljanje i ispitivanje oralne tekućine za prikupljanje oralne tekućine i ispitivanje oralne tekućine na pripravka, naprava za ispitivanje obuhvaća:
However, the essentially inactive (-)-a-[11C]dihydrotetrabenazine isomer was almost uniformly distributed in the brain, suggesting that specific binding to DAT and VMAT2 was not occurring. 
Doduše, esencijalno neaktivan (-)-a -['"C]dihidrotetrabenazin izomer je bio gotovo jednolično raspodijeljen u mozgu, ukazujući da nije došlo do specifičnog vezivanja na DAT i VMAT2.
The monohydrate form exhibited characteristic signals with chemical shift values of -64.5, -114.7, -136.3, and -146.2 p.p.m. 
Monohidratni oblik pokazao je karakteristične signale sa vrijednostima kemijskog pomaka od -64.5, -114.7, -136.3, i -146.2 p.p.m.
The insertion system (100) according to claim 4, wherein the second lumen defined by the second catheter tube (42) has a diameter sufficient to accommodate a guide wire (180). 
Sustav za umetanje (100) prema zahtjevu 4, gdje drugi lumen definiran drugom kateterskom cjevčicom (42) ima promjer dovoljan za smještaj provodne žice
where R1, R3-R13 are as defined herein and R′ is a protection group such as a carbamate (such as methyl-, ethyl-, tert-butyl-, allyl-, or benzyl-carbamate); whereupon the compound of formula IC is isolated as the free base or a salt such as a pharmaceutically acceptable acid addition salt thereof. 
QA) gdje su R', R*-R'* kako je to ovdje definirano i R' je protekcijska grupa kao karbamati (kao što je to metil-, etil-, tert- butil, alil-, ili benzil-karbamat) nakon čega se spoj formule IC izolira kao slobodna baza ili njezina sol kao farmaceutski prihvatljiva kisela dodatna njezina sol.
The process of item 15, wherein the temperature of step c) is the target exhaust air temperature and wherein the curing step starts when the exhaust air temperature reaches said temperature and the curing step ends either when the heating is stopped or at least reduced and the exhaust air temperature subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the exhaust air temperature drops below said temperature in a parabolic or triangular temperature profile. 
Postupak prema zahtjevu 15, naznačen time da je temperatura u koraku c) ciljana izlazna temperatura zraka i gdje korak stvrdnjavanja započinje kada izlazna temperatura zraka dostigne navedenu temperaturu i gdje korak stvrdnjavanja završava ili kada se zaustavi zagrijavanje ili kada je barem smanjeno te izlazna temperatura zraka naknadno pada ispod navedene temperature za više od oko 10 "C ili ispod oko 62 "C, u temperaturnom profilu nalik platou ili kada izlazna temperatura pada ispod navedene temperature u paraboličnom ili trokutastom temperaturnom profilu.
After filling lyophilization stoppers were placed and the vials were loaded in the lyophiliser at 5°C. 
Nakon punjenja postavljeni su čepovi za liofilizaciju i ampule postavljene u liofilizator na 5?C.
A preferred mill is a Fitz mill. 
Povoljan mlin je Fitz mlin.
a Cas9 polypeptide, or a polynucleotide encoding said Cas9 polypeptide, and a DNA-targeting RNA, or one or more DNA polynucleotides encoding said DNA-targeting RNA, wherein the DNA-targeting RNA comprises: a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA, and 
polipeptid Cas9, ili polinukleotid koji kodira navedeni polipeptid Cas9, i RNA koja cilja na DNA, ili jedan ili više DNA polinukleotida koji kodiraju navedenu RNA koja cilja na DNA, gdje RNA koja cilja na DNA sadrži: segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran slijedu u ciljanoj DNA, i
The method of claim 4 wherein A is COOH. The method of claim 1 wherein the compound is selected from the group consisting of 4-(6-hydroxy-3-methylquinolin-2-yl)benzoic acid; 
Spoj ili sol prema zahtjevu 4, naznačen/a time, da A je COOH. 6. Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: 4-(6-hidroksi-3-metilkinolin-2-il)benzoeva kiselina;
The solvent is removed in vacuo and the resulting crude residue is loaded on a pre-packed Isolute™ silica column and eluted with iso-hexane/ethyl acetate (4:1) to yield the titled compound as a white powder. 
Otapalo se odstrani u vakuumu i dobiveni sirov ostatak se stavi na pred-pakirani Isolute'" stupac silika gela 1 ispere se izo-heksan/etil acetatom (4:1), čime se dobije naslovni spoj kao bijeli prah.
The use according to any one of claims 26 to 28, wherein said anti-C5 antibody, said inhibitor of IL-2, and said immunosuppressive drug that is not associated with significant nephrotoxicity are in a formulation suitable for concurrent administration to said recipient mammal or wherein said anti-C5 antibody, said inhibitor of IL-2 and said immunosuppressive drug that is not associated with significant nephrotoxicity are in a formulation or formulations suitable for sequential administration to said recipient mammal. 
Uporaba prema bilo kojem od zahtjeva 26 do 28, naznačena time, što su spomenuto anti-C5 antitijelo, spomenuti inhibitor IL-2 i spomenuti imunosupresivni lijek koji nije udružen sa značajnom nefrotoksičnošću u formulaciji pogodnoj za istovremenu primjenu kod spomenutog sisavca primatelja ili pri čemu su spomenuto anti-C5 antitijelo, spomenuti inhibitor 1L-2 i spomenuti imunosupresivni lijek koji nije udružen sa značajnom nefrotoksičnošću u formulaciji ili formulacijama pogodnim za sekvencijalnu primjenu kod spomenutog sisavca primatelja.
or a pharmaceutically acceptable salt or solvate form thereof, wherein L is the antibody or antigen-binding fragment of claim 1 and p is from 1 to 8. 
be S AE P ili njegova farmaceutski prihvatljiva sol ili solvat, pri čemu L je protutijelo i p je od 1 do 8.
The molecule according to claim 6 wherein said molecule retains at least 80% of native FVIII biological activity. 
Molekula prema zahtjevu 6, pri čemu navedena molekula zadržava barem 80% prirodne biološke aktivnosti FVIII.
A composition comprising: an adjuvant, which adjuvant is an alkoxylated fatty acid or alkoxylated fatty alcohol, which adjuvant has the formula I; 
Pripravak koji sadrži: a) pomoćno sredstvo, navedeno pomoćno sredstvo je alkoksilirana masna kiselina ili alkoksilirani masni alkohol, te navedeno pomoćno sredstvo ima formulu I;
The results are shown in table 15 and are expressed as percentage of death cells. 
Rezultati su prikazani u tablici 15 1 izraženi su kao postotak mrtvih stanica.
a glass valve retainer in the neck of the container such that at least a portion of a radially outer surface of the valve retainer is in indirect contact with the interior surface of the neck by way of bonding material, a glass plug in the neck of the container and in the valve retainer such that at least a portion of a radially inner surface of the valve retainer is in indirect contact with a radially outer surface of the plug by way of bonding material, and 
162, 262, 462) radijalno prema unutra unutarnje površine tijela, i kuglu ventila (38, 138, 238, 338, 438, 538). koja se nalazi u unutarnjem prolazu grla spremnika između tijela ventila i zatvarača; gdje je u najmanju ruku dio radijalne vanjske površine tijela ventila u posrednom kontaktu s unutarnjom površinom grla spremnika uz pomoć vezivnog materijala.
Cy is independently selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. 
Cy se neovisno odabire od supstituiranog ili nesupstituiranog cikloalkila, supstituirane ili nesupstituirane heterocikličke skupine, supstituiranog ili nesupstituiranog arila i supstituiranog ili nesupstituiranog heteroarila.
Dehydration of the dihydrotetrabenazine to the alkene (II) can be carried out using a variety of standard conditions for dehydrating alcohols to form alkenes, see for example J. 
Dehidriranje dihidrotetrabenazina do alkena (II) se može provesti korištenjem različitih standardnih uvjeta za dehidriranje alkohola do alkena, vidi na primjer J.
Aspect 28. The elongate wick of aspect 21 wherein the elongate wick is resistant to thermal degradation up to a temperature of at least about 180° C. 
Izduženi fitilj (30) prema zahtjevu 18, pri čemu je izduženi fitilj otporan na toplinsku razgradnju do temperature od najmanje 180 *C.
The method of claim 1, wherein the breast cancer is a locally advanced breast cancer. 
Kombinacija za uporabu prema zahtjevu 1, gdje je rak dojke lokalno uznapredovali rak dojke.
A further aspect of the present invention provides Compound 1, a substantially pure diastereomer thereof, or a pharmaceutically acceptable salt thereof, or Compound 2, a substantially pure diastereomer thereof, or a pharmaceutically acceptable salt thereof, for use in the treatment of T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroleukemia, triple negative breast cancer, breast cancer, ovarian cancer, melanoma, lung cancer, non small cell lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral squamous cell carcinoma, skin cancer, medulloblastoma, angiosarcoma, rhabdomyosarcoma, liposarcoma, malignant fibrous histiocytoma, hepatocellular carcinoma, intrahepatic or extrahepatic cholangiocarcinoma, or adenoid cystic carcinoma. 
Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju akutne limfoblastične leukemije 'T-stanica, akutne limfoblastične leukemije, kronične limfoblastične leukemije, akutne mijelogene leukemije, kronične mijelogene leukemije, eritroleukemije, trostruko negativnog raka dojke, raka dojke, raka jajnika, melanoma, raka pluća, raka velikih stanica pluća, raka gušterače, glioblastoma, kolorektalnog rak, raka glave i vrata, raka vrata maternice, raka prostate, raka jetre, oral karcinoma pločastih stanica, raka kože, meduloblastoma, = angiosarkoma, = rabdomiosarkoma, = liposarkoma, = zloćudnog = fibroznog = histiocitoma, hepatocelularnog karcinoma, intrahepatičnog ili ekstrahepatičnog kolangiokarcinoma ili adenoidnog cističnog karcinoma.
The method of claim 1, wherein the generating of the luma sample comprises: scaling the luma sample generated by applying the 8-tap filter by using a luma scaling factor that a sum of coefficients of the 8-tap filter is 1. 
Postupak prema patentnom zahtjevu 1, naznačen time da generiranje uzorka osvjetljenja sadrži skaliranje uzorka osvjetljenja koji je generiran upotrebom 8-tap filtera upotrebom faktora skaliranja osvjetljenja 64 da bi se rekonstruirala dubina bita uzorka osvjetljenja.
Many implements use pneumatic power to move forage 8, so it is basically fluidized in pressurized air. 
Mnogi uređaji koriste pneumatske uređaje za pomicanje krupne stočne hrane 8, tako da se ona u biti fluidizira u zraku pod tlakom.
The lipophilic matrix of the present invention is represented by substances having a melting point lower than 90° C., such as, for example, beeswax, carnauba wax, stearic acid, stearin and the like; the amphiphilic matrix is represented by substances selected, for example, from phospholipids, ceramides, sphingomyelins, lecithins, alkyl block copolymers, salts of sulphated alkyl acids, polyoxyethylenated alkyl, derivatives of sorbitan and the like, while the hydrophilic matrix is represented by generally cross-linked or linear polymeric or copolymeric substances, which are known as hydrogels, that is to say, substances capable of increasing their mass and their weight, owing to the polar groups present in the main or side polymer chains, when they come into contact with molecules of water. 
Lipofilni kalup ovog izuma čine tvari koje imaju točku tališta manju od 90"C, kao što su na primjer pčelinji vosak, karnauba vosak, stearinska kiselina, stearin i slično; amfifilni kalup čine tvari odabrane iz grupe koja sadrži na primjer fosfolipide, ceramide, sfingomijeline, lecitine, alkil blok kopolimere, soli sulfatnih alkil kiselina, polioksietilenirani alkil, derivate sorbitana 1 sličnog, dok hidrofilni kalup čine općenito križno vezano ili linearne polimerne ili kopolimerne tvari poznate kao hidrogelovi, odnosno tvari koje imaju svojstvo povećavanja svoje mase 1 težine nakon što dođu u kontakt s molekulama vode i to zahvaljujući polarnim grupama prisutnima na glavnom ili sporednim polimernim lancima.
A double stranded RNAi agent of claims 1 or a pharmaceutical composition of claim 6 or 7 for use in a method of reducing the accumulation of misfolded Serpinal in the liver of a subject having a Serpinal deficiency variant. 
Dvolančano RNAi sredstvo prema zahtjevu 1 ili farmaceutski pripravak prema zahtjevu 6 ili 7 za uporabu u postupku za smanjenje nakupljanja pogrešno složenog Serpinal u jetri subjekta koji ima varijantu nedostatka Serpinal.
The oxidants may be chosen from hydrogen peroxide, carbamide peroxide and benzoyl peroxide. The wound healing composition may further comprise at least one hydrophilic gelling agent. The hydrophilic gelling agent may be chosen from glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, Carbopol® polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1, gdje peroksid je odabran iz grupe koja se sastoji od vodik peroksida pri 3.5% do 6% ukupne kompozicije, karbamid peroksida pri 10% do 16% ukupne kompozicije, i benzoil peroksida pri 2.5% do 5% ukupne kompozicije Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
A method for improving the herbicidal effect of (1) a herbicidal sulfonylurea compound or its salt, by using (2) a polyoxyalkylene (POA) alkyl ether phosphate or its salt, wherein the number of addition of POA moiety in the POA alkyl ether phosphate is from 1 to 50. 
Postupak za poboljšavanje učinka herbicida iz (1) spoja sulfonil ureja herbicida ili soli istog uporabom (2) polioksialkilen (POA) alkil eter fosfata ili soli istog, naznačen time, da je broj dodavanja polovice POA u POA alkil eter fosfatu u omjeru od 1 do 50.
Glatiramer acetate for use according to claim 1 or 3, or a medicament comprising glatiramer acetate for use according to claim 2 or 3, wherein the human patient is suffering from relapsing-remitting multiple sclerosis. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da čovjek kao pacijent nije primio terapiju glatiramer acetatom prije početka liječenja.
Amides of the formula V can be prepared by coupling of the corresponding benzoic acids (synthesised by methods analogous to those described in e.g. 
Amidi formule V mogu se pripremati spajanjem odgovarajućih benzoičnih kiselina (sintetiziranima metodama analognim onima opisanim u Hamel, P; Girard, M.; Tsou, N.N.
The monoclonal antibody of claim 2, wherein said colorectal cancer cells are LS174T cells. 
Monoklonalno antitijelo iz patentnog zahtjeva 2, naznačeno time da rečene kolorektalne stanice karcinoma jesu LS174T stanice.
A method according to claim 1 comprising the further steps: using a rate to transmit payload data at the higher data rate; and locating a representation of the rate in the frame before the transmission at the payload data at the higher data rate. 
Postupak prema zahtjevu 1, naznačen time, da nadalje obuhvaća sljedeće korake: uporaba jedne brzine prijenosa u svrhu prijenosa skupova korisničkih informacija (36) uz veću podatkovnu brzinu; i lociranje predstavljanja brzine prijenosa u okviru prije izvršenja prijenosa skupova korisničkih informacija (36) uz veću podatkovnu brzinu.
The process according to any one of claims 1 to 21, characterized in that the at least one partially or totally lithium-neutralized water-soluble organic polymer is present in an amount of from 0.001 wt% to 5 wt%, preferably from 0.01 wt% to 2 wt%, and most preferably from 0.05 wt% to 1 wt%, relative to the total dry mineral material. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 14, karakteriziran na način da je barem jedan djelomično ili potpuno litijem neutraliziran u vodi topljiv organski polimer prisutan u količini od 0.001 wt% do 5 wt%, poželjno od 0.01 wt% do 2 wt%, najpoželjnije od 0.05 wt% do 1 wt%, u odnosu na ukupni suhi mineralni materijal.
The composition of claim 1, wherein the polyalkylsiloxane is polydimethylsiloxane and the viscosity is 200 mm2.s-1(cSt). 
Pripravak iz patentnog zahtjeva 1, naznačen time, da je polialkilsiloksan polidimetilsiloksan, a viskozitet je 200 mm".s! (cS0).
Sorbic acid, a sorbic acid salt, or a sorbic acid derivative for use in a method of mitigating one or more symptoms of a neuropsychiatric disorder, wherein the sorbic acid salt is selected from the group consisting of sodium sorbate, potassium sorbate, and calcium sorbate; the sorbic acid derivative is selected from the group consisting of sorbohydroxamic acid, sorbic aldehyde, sorbic acid-thiol adduct, 8-quinolinylsorbate, and m-nitrosorbanilide; 
Benzojeva kiselina ili sol benzojeve kiseline za uporabu u metodi ublažavanja jednog ili više simptoma shizofrenije pri čemu se sol benzojeve kiseline bira iz skupine koja se sastoji od natrijevog benzoata, kalijevog benzoata, kalcijevog benzoata i litijevog benzoata i pri čemu je količina benzojeve kiseline ili soli benzojeve kiseline dovoljna za ublažavanje jednog ili više spomenutih simptoma i varira od približno 5 mg do približno 500g.
RC1, RC2 RC3 and RC4 are each independently selected from hydrogen, methyl, ethyl, hydroxymethyl, hydroxyethyl, methoxymethyl, methoxyethyl, 2,2,2-trifluoroethyl, or 
RI, RČ RS iR" su svaki nezavisno odabrani od vodika, metila, etila, hidroksimetila, hidroksietila, metoksimetila, metoksietila, 2,2,2-trifluoroetila, ili
The method of claim 1, wherein at least a portion of the compound is present as a polymorphic form, wherein the polymorphic form is a crystalline form having an X-ray diffraction pattern (CuKa) comprising significant diffraction peaks at about 8.8, 12.9, 13.4, 14.2and 17.4 °2θ. 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 19 do 23, naznačen time što je u najmanju ruku dio spoja prisutan kao kristalni oblik s uzorkom difrakcije rendgenskih zraka (CuKa) koji sadrži značajne difrakcijske maksimume na otprilike 8,8, 12,9, 13,4, 14,21 17,4" 26.